3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
56
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
29
Neoplasm Metastasis
23
Glioblastoma
23
Colonic Neoplasms
23
Rectal Neoplasms
19
Ovarian Neoplasms
16
Neoplasms
15
Brain Neoplasms
12
Lung Neoplasms
11
Pancreatic Neoplasms
10
Glioma
10
Fallopian Tube Neoplasms
10
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
9
Gliosarcoma
7
Adenocarcinoma of Lung
7
Kidney Neoplasms
6
Liver Neoplasms
5
Astrocytoma
5
Sarcoma
4
Recurrence
4
Oligodendroglioma
4
Melanoma
4
Uterine Cervical Neoplasms
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Interventions
apaziquone
4
Mitomycin
3
viscum album peptide
1
valrubicin
1
pembrolizumab
1
linrodostat
1
enzalutamide
1
enfortumab vedotin
1
avelumab
1
Sugars
1
Standard of Care
1
Polysorbates
1
Pentosan Sulfuric Polyester
1
Nivolumab
1
Gemcitabine
1
DDMS
1
Capsules
1
Bevacizumab
1
ALT-801
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Non-Muscle Invasive Bladder Neoplasms
×
Bevacizumab
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled